Context Therapeutics
CNTX
39 hedge funds and large institutions have $45M invested in Context Therapeutics in 2025 Q2 according to their latest regulatory filings, with 4 funds opening new positions, 9 increasing their positions, 9 reducing their positions, and 7 closing their positions.
3% more capital invested
Capital invested by funds: $43.7M → $45M (+$1.25M)
0% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 9
3.11% less ownership
Funds ownership: 79.61% → 76.5% (-3.1%)
7% less funds holding
Funds holding: 42 → 39 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LM
Luminus Management
Houston,
Texas
|
+$236K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$77K |
| 3 |
MCCA
Mill Creek Capital Advisors
Conshohocken,
Pennsylvania
|
+$75.2K |
| 4 |
GS
GTS Securities
Miami,
Florida
|
+$31.8K |
| 5 |
BOCH
Blue Owl Capital Holdings
New York
|
+$28.8K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ABG
Ally Bridge Group
New York
|
-$708K |
| 2 |
AI
Allostery Investments
Stamford,
Connecticut
|
-$582K |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$490K |
| 4 |
SC
Shay Capital
New York
|
-$116K |
| 5 |
AAA
Affinity Asset Advisors
New York
|
-$103K |
CNTX Hedge Fund Activity: Q2 2025 in Review
39 of the 7,616 institutional investors tracked by Wall St. Rank reported a position in Context Therapeutics (CNTX) for Q2 2025, worth a combined $45M — up 2.9% from $43.7M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of CNTX and 4 opened new positions — a net loss of 3 holders — while 9 trimmed existing stakes and 9 added.
The largest buyer was Luminus Management, opening a new position worth an estimated $236K. The largest seller was Ally Bridge Group, exiting entirely with an estimated $708K sold.
- 39 institutional investors held Context Therapeutics (CNTX) as of Q2 2025, down from 42 in Q1 2025.
- Funds reported $45M of Context Therapeutics stock for Q2 2025, up 2.9% quarter-over-quarter.
- 4 funds opened new Context Therapeutics positions in Q2 2025 and 7 closed out, a net change of -3 holders.
- The largest Context Therapeutics buyer in Q2 2025 was Luminus Management, an estimated $236K added.
- The largest Context Therapeutics seller in Q2 2025 was Ally Bridge Group, an estimated $708K sold.
Based on aggregated 13F filings for Q2 2025.